loading
前日終値:
$144.16
開ける:
$142.99
24時間の取引高:
642.91K
Relative Volume:
0.72
時価総額:
$14.37B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
49.11
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
-4.93%
1か月 パフォーマンス:
+5.56%
6か月 パフォーマンス:
+21.96%
1年 パフォーマンス:
+17.89%
1日の値動き範囲:
Value
$142.99
$146.38
1週間の範囲:
Value
$142.99
$154.10
52週間の値動き範囲:
Value
$84.23
$157.67

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1135)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,800
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
144.86 14.37B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
120.82 53.39B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.29 44.99B 29.63B 260.53M 5.51B 0.0788
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.59 44.08B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
25.41 29.30B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
466.40 19.91B 3.08B 1.24B 1.07B 25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
02:56 AM

Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfolios2025 Big Picture & Technical Entry and Exit Alerts - newser.com

02:56 AM
pulisher
02:46 AM

Why Neurocrine Biosciences Inc. stock remains resilientPortfolio Performance Report & Real-Time Stock Movement Alerts - newser.com

02:46 AM
pulisher
Nov 14, 2025

What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investors2025 Sector Review & Low Risk High Win Rate Picks - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Can Neurocrine Biosciences Inc. stock weather global recessionEarnings Miss & Community Driven Trade Alerts - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Is Neurocrine Biosciences Inc. stock trading near support levelsJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusTrade Volume Summary & Consistent Profit Alerts - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

How Neurocrine Biosciences Inc. stock responds to policy changesWeekly Profit Report & Consistent Return Strategy Ideas - newser.com

Nov 14, 2025
pulisher
Nov 13, 2025

Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

Is it time to cut losses on Neurocrine Biosciences Inc.Weekly Trend Recap & Technical Confirmation Alerts - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growthTake Profit & Risk Controlled Daily Trade Plans - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

Measuring Neurocrine Biosciences Inc.’s beta against major indicesPortfolio Risk Summary & Daily Stock Trend Watchlist - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

What data driven models say about Neurocrine Biosciences Inc.’s futureJobs Report & Smart Swing Trading Alerts - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

How to build a dashboard for Neurocrine Biosciences Inc. stockWeekly Market Summary & Expert Approved Momentum Ideas - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Risk Review & Expert Curated Trade Setup Alerts - newser.com

Nov 13, 2025
pulisher
Nov 12, 2025

Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance

Nov 12, 2025
pulisher
Nov 12, 2025

What analysts say about Neurocrine Biosciences Inc stockPrice Volatility Patterns & Small Budget Growth - earlytimes.in

Nov 12, 2025
pulisher
Nov 12, 2025

Neurocrine Biosciences to Present at Upcoming Investor Conferences - Your Wyoming Link

Nov 12, 2025
pulisher
Nov 12, 2025

Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News - Yahoo Finance

Nov 12, 2025
pulisher
Nov 12, 2025

What analysts say about Neurocrine Biosciences Inc NB3 stockSector Performance Review & Free Turn Volatility To Profit - earlytimes.in

Nov 12, 2025
pulisher
Nov 12, 2025

Neurocrine’s depression candidate fails mid-stage study but analysis continues - The Pharma Letter

Nov 12, 2025
pulisher
Nov 12, 2025

Neurocrine Biosciences (NBIX): Assessing Valuation After Lead Depression Drug Misses Phase 2 Study Goal - simplywall.st

Nov 12, 2025
pulisher
Nov 12, 2025

What valuation multiples suggest for Neurocrine Biosciences Inc. stockPortfolio Value Summary & Daily Volume Surge Signals - newser.com

Nov 12, 2025
pulisher
Nov 12, 2025

Neurocrine Biosciences fails mid-stage study of depression drug - MSN

Nov 12, 2025
pulisher
Nov 11, 2025

Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression - MedCity News

Nov 11, 2025
pulisher
Nov 11, 2025

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice - sharewise.com

Nov 11, 2025
pulisher
Nov 11, 2025

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga

Nov 11, 2025
pulisher
Nov 11, 2025

Neurocrine’s Depression Drug Misses In Phase II - Citeline News & Insights

Nov 11, 2025
pulisher
Nov 11, 2025

Morgan Stanley Lowers Price Target for Neurocrine Biosciences (N - GuruFocus

Nov 11, 2025
pulisher
Nov 11, 2025

Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study - MarketScreener

Nov 11, 2025
pulisher
Nov 11, 2025

Neurocrine’s depression drug fails to meet primary endpoint in phase 2 - Investing.com Nigeria

Nov 11, 2025
pulisher
Nov 10, 2025

Neurocrine’s depression drug fails to meet primary endpoint in phase 2 By Investing.com - Investing.com South Africa

Nov 10, 2025
pulisher
Nov 10, 2025

Neurocrine chalks up a depression drug failure - BioPharma Dive

Nov 10, 2025

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$10.72
price down icon 1.74%
drug_manufacturers_specialty_generic RDY
$13.94
price up icon 0.50%
$21.09
price down icon 4.09%
$36.98
price up icon 2.58%
$466.40
price up icon 0.89%
大文字化:     |  ボリューム (24 時間):